Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.

Oncotarget - 6 Dec 2016

Wu Ran, Cheng Yi-Ju, Zhu Li-Li, Yu Lei, Zhao Xue-Ke, Jia Min, Wen Chang-Hui, Long Xing-Zhen, Tang Ting, He Ai-Juan, Zeng Yi-Yan, Ma Zun-Feng, Zheng Zhi, Ni Mu-Zi, Cai Gong-Jing

Abstract excerpt

Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). Recently, HLA-B*58:01 allele was identified as a strong genetic marker for allopurinol-induced CADRs in Han Chinese. However, the magnitude of association and diagnosis value of HLA-B*58:01 in allopurinol-induced CADRs remain inconclusive. To investigate this inconsistency, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allopurinol
Share to Drug Eruptions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gout Suppressants

Share to HLA-B Antigens

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 27835909
DOI: 10.18632/oncotarget.13250
PMCID: PMC5348437

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.PMID 27835909Read ↗

Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.Semantic proximity Read ↗

Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.Semantic proximity Read ↗

HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.Semantic proximity Read ↗

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.Semantic proximity Read ↗

Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.Semantic proximity Read ↗

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.Semantic proximity Read ↗

HLA-B*58:01 is an Incomplete Predictor of Allopurinol-Induced Severe Cutaneous Adverse ReactionsSemantic proximity Read ↗

Influence of pharmacogenomic polymorphisms on allopurinol-induced cutaneous adverse drug reactions in Thai patients.Semantic proximity Read ↗

Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions.Semantic proximity Read ↗

Comparison between the HLA-B∗58 : 01 Allele and Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions.Semantic proximity Read ↗

HLA-B*58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in ThailandSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.